ABH 001

Drug Profile

ABH 001

Alternative Names: ABH-001; Dermagraft; Human fibroblast-derived dermal substitute

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Epidermolysis bullosa

Most Recent Events

  • 17 Jan 2014 Organogenesis acquires ABH 001 from Shire
  • 07 Oct 2013 Shire completes enrolment in its phase III trial for Epidermolysis bullosa in USA, Canada, Austria, France, Germany, Poland, Portugal & Spain (NCT01749306)
  • 30 Sep 2013 Discontinued - Phase-III for Epidermolysis bullosa in USA , Spain, Austria, Germany, Portugal, Canada, Poland and France (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top